<DOC>
	<DOCNO>NCT00139711</DOCNO>
	<brief_summary>A multicenter randomize phase II study evaluate activity tolerability three different combination docetaxel ( taxotere ) irinotecan ( campto ) second line therapy recurrent metastatic non small cell lung cancer ( NSCLC )</brief_summary>
	<brief_title>Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically cytologically proven NSCLC Recurrent metastatic NCSLC Prior malignancy ; except cure non melanoma skin cancer , curatively treat situ carcinoma cervix cancer adequately treat non evidence disease least 5 year History presence brain meningeal metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>